CONDENSED BALANCE SHEETS - USD ($) $ in Thousands	Sep. 30, 2015	Dec. 31, 2014
Current assets:
Cash and cash equivalents	$ 46,116	$ 35,014
Accounts receivable, net of allowance of $92 and $84 as of September 30, 2015 and December 2014, respectively	3,520	3,050
Supplies inventory	3,984	3,696
Prepaid expenses and other current assets	3,371	1,218
Deferred tax asset	222	300
Restricted cash	118	70
Total current assets	57,331	43,348
Property and equipment, net	6,200	4,161
Finite-lived intangible assets, net	15,467
Indefinite-lived intangible assets: in-process research and development		16,000
Goodwill	1,057	1,057
Restricted cash	603	118
Other assets	195	155
Total assets	80,853	64,839
Current liabilities:
Accounts payable	6,644	7,397
Accrued liabilities	7,365	7,851
Deferred Genzyme co-promotion fee	1,423	1,897
Total current liabilities	15,432	17,145
Long-term debt	5,002	4,923
Deferred tax liability	222	300
Deferred rent, net of current portion	2,386	149
Deferred Genzyme co-promotion fee, net of current portion		948
Total liabilities	$ 23,042	$ 23,465
Commitments and contingencies
Stockholders' equity:
Preferred stock, $0.001 par value; 5,000,000 shares authorized, no shares issued and outstanding as of September 30, 2015 and December 31, 2014
Common stock, $0.001 par value; 125,000,000 shares authorized, 27,657,030 and 22,523,529 shares issued and outstanding as of September 30, 2015 and December 31, 2014, respectively	$ 27	$ 23
Additional paid-in capital	198,497	156,373
Accumulated deficit	(140,713)	(115,022)
Total stockholders' equity	57,811	41,374
Total liabilities and stockholders' equity	$ 80,853	$ 64,839